Neoadjuvant Chemotherapy Induces Expression Levels of Breast Cancer Resistance Protein That Predict Disease-Free Survival in Breast Cancer

• Baek Kim,

  Affiliations Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, Department of Breast Surgery, Leeds General Infirmary, Leeds, United Kingdom

  ⨯
• Hiba Fatayer,

  Affiliation Department of Breast Surgery, Leeds General Infirmary, Leeds, United Kingdom

  ⨯
• Andrew M. Hanby,

  Affiliation Department of Histopathology, St. James’s University Hospital, Leeds, United Kingdom

  ⨯
• Kieran Horgan,

  Affiliation Department of Breast Surgery, Leeds General Infirmary, Leeds, United Kingdom

  ⨯
• Sarah L. Perry,

  Affiliation Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom

  ⨯
• Elizabeth M.A. Valleley,

  Affiliation Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom

  ⨯
• Eldo T. Verghese,

  Affiliation Department of Histopathology, St. James’s University Hospital, Leeds, United Kingdom

  ⨯
• Bethany J. Williams,

  Affiliation Department of Histopathology, St. James’s University Hospital, Leeds, United Kingdom

  ⨯
• James L. Thorne,

  Affiliation Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom

  ⨯
• Thomas A. Hughes

  * E-mail: t.hughes@leeds.ac.uk

  Affiliation Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom

  ⨯